Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients

• DOI: 10.1126/scitranslmed.aaa2327
• Publication Date: 2015-04-15T18:15:00Z
• Authors: Michaela Semeraro; Sylvie Rusakiewicz; Véronique Minard-...; Nicolas F. Delahaye; David Enot; Frédéric Vély; Aurélien Marabelle; Benjamin Papoular; Christelle Pipero...; Mirco Ponzoni; Patrizia Perri; Andrei Tchirkov; Jessica Matta; Valérie Lapierre; Tala Shekarian; Sandrine Valsesia...; Frédéric Commo; Nicole Prada; Vichnou Poirier-C...; Brigitte Bressac; Sophie Cotteret; Laurence Brugieres; Françoise Farace; Nathalie Chaput; Guido Kroemer; Dominique Valteau...; Laurence Zitvogel
• Keywords: Adult; B7 Antigens; Natural Cytotoxicity Triggering Receptor 3; Adolescent; Brain Neoplasms; Infant; Antineoplastic Agents; Ligands; Disease-Free Survival; 3. Good health; Gene Expression Regulation, Neoplastic; Jurkat Cells; Neuroblastoma; 03 medical and health sciences; Phenotype; 0302 clinical medicine; Cell Line, Tumor; Child, Preschool; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Humans; Neoplasm Metastasis; Child

Natural killer cell activity and NKp30/B7-H6 interaction are prognostic biomarkers in high-risk neuroblastoma patients.